+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Europe Lab-on-a-chip and Microarrays (Biochip) Market - Segmented by Product, Application, Technology, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4591880
  • Report
  • May 2018
  • Region: Europe
  • 88 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Aastrom Biosciences
  • Athersys
  • Biomerieux SA
  • Celgene Corporation
  • Oxford Gene Technologies
  • Roche Holding AG
  • MORE
The Europe lab-on-a-chip and microarrays (biochip) market is expected to register a high CAGR during the forecast period, 2018 to 2023. A biochip is a collection of miniaturized test sites (microarrays) arranged on a solid substrate that permits many tests to be performed at the same time, to achieve higher throughput and speed. Typically, a biochip's surface area is no larger than a fingernail. Like a computer chip, that can perform millions of mathematical operations in one-second, a biochip can perform thousands of biological reactions, such as decoding genes, in a few seconds.

Increasing Application of Biochips in Proteomics

Biochips are being increasingly used in the area of biomedical and biotechnological research. With the advancement of technology in the medical field, there has been a rise in adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include low sample consumption and its inclination towards miniaturization. For instance, protein microarrays can display multiple proteins simultaneously, and these characteristics translate into its ability to process thousands of samples parallelly. This characteristic of microarrays is important for proteome-wide analysis. Proteomics is being widely adopted for biomarker discovery and drug discovery. Moreover, the rise in demand for personalized medicine for diseases is contributing to the growth of the market. The other factors, such as increasing use of biochips in cancer treatment and diagnostics, and rapid technological advances in biochip technology are driving the lab-on-a-chip and microarrays (biochip) market.

Availability of Alternative Technologies

Microarrays (biochips) has been the technology of choice for large-scale studies of gene expression since their invention in the 1990s. Although microarray technology continues to advance, transcriptomics has expanded dramatically in the past few years, owing to the availability of new alternative technology, such as RNA-sequencing (RNA-seq) and Next Generation Sequencing (NGS).

Both sensitivity and specificity can be low with microarray technology. Moreover, accuracy can be negatively affected, owing to a low dynamic range of the existing microarrays. Background hybridization limits the accuracy of expression measurements, especially for transcripts present in small amounts. Probes also differ considerably in their hybridization properties. Microarrays are limited to interrogating only those genes for which probes are designed. Although microarray technology has its advantages (less labor intensive and economical), the availability of alternative technologies and their benefits in comparison with microarrays is restraining the growth of lab-on-a-chip and microarrays (biochip) market. The other factors, such as low commercial acceptability due to the high costs and lack of skilled labor is also hindering the market.

Germany Lead the Market in Europe Region

The German lab-on-a-chip and microarrays (biochip) market held the largest market share in 2017 in Europe due to the presence of high-quality healthcare system. The biochip market has recently started in the emerging nations, wherein major investments are expected to happen.

Key Developments in the Market:
  • June 2017: Biochips for wound healing - Complex biology and chip technology have been combined at the Vienna University of Technology. This enables customized, personalized medicine on the smallest spaces. For the first time, a chip for wound healing measurement was introduced publicly at an international expert audience in the exhibition “Labvolution”.

Reasons to Purchase the Report
  • Follow the current and future European lab-on-a-chip and microarrays (biochip) market in the developed and emerging markets.
  • Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
  • Identify the segment that is expected to dominate the market.
  • Identify the regions that are expected to witness the fastest growth during the forecast period.
  • Identify the latest developments, market shares, and strategies employed by the major market players.
  • 3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report

This report can be customized to meet your requirements.
This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Aastrom Biosciences
  • Athersys
  • Biomerieux SA
  • Celgene Corporation
  • Oxford Gene Technologies
  • Roche Holding AG
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Increasing Application of Biochips in Proteomics
6.1.2 Increasing use of Biochips in Cancer Treatment and Diagnostics
6.1.3 Rapid Technological Advances in Biochip Technology
6.2 Restraints
6.2.1 Low Commercial Acceptability due to High Cost
6.2.2 Availability of Alternate Technologies
6.2.3 Lack of Skilled Labor
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Products
7.1.1 DNA Microarrays
7.1.2 Lab-on-a-chip / Microfluidics
7.1.3 Protein Microarrays
7.1.4 Tissue Biochips
7.1.5 Others
7.2 By Applications
7.2.1 Genomics
7.2.2 Proteomics
7.2.3 Cancer Research
7.2.4 Drug Discovery
7.2.5 Clinical Diagnosis
7.2.6 Toxicogenomics
7.2.7 Others
7.3 By Technologies
7.3.1 Microarrays
7.3.2 Microfluidics
7.4 By Geography
7.4.1 Europe France Germany United Kingdom Italy Spain Rest of Europe

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Aastrom Biosciences
9.2 Athersys
9.3 Biomerieux SA
9.4 Celgene Corporation
9.5 Oxford Gene Technologies
9.6 Roche Holding AG
*List Not Exhaustive

10. Future of the Market

11. Disclaimer
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Oxford Gene Technologies
  • Aastrom Biosciences
  • Celgene Corporation
  • Biomerieux SA
  • Athersys
  • Roche Holding AG
Note: Product cover images may vary from those shown